Frontiers editorial tracks rise of natural compounds in vet therapeutics
Bottom line
Frontiers in Veterinary Science on September 2, 2026, published an editorial summarizing its research topic “Natural compounds in veterinary therapeutics, volume II,” with Baocheng Hao, Dongan Cui, and Shuaiyu Wang highlighting a growing body of work on plant-, animal-, and microbe-derived bioactive compounds for veterinary use. The editorial points to studies on the chemical characterization of Neurexan, gut-health interventions in weaned piglets using short-chain fructooligosaccharides, essential oils, and sodium humate, dandelion-derived polysaccharides in lambs, chlorogenic acid in a mouse kidney injury model, and valonea tannin supplementation in broilers. Across the collection, the common thread is a push toward more defined, mechanism-based use of natural compounds, especially as alternatives or complements to conventional antimicrobials in food-animal systems. (frontiersin.org)
Why it matters: For veterinary professionals, the editorial is less a practice-changing paper than a signal about where pharmacology research is heading: toward multi-target compounds that may support intestinal health, immune modulation, inflammation control, and productivity in production animals. That direction aligns with years of industry and research focus on reducing antibiotic use, but experts have also cautioned that alternatives need clearer mechanisms, better standardization, and stronger field-efficacy data before they can be relied on consistently across farms and species. (frontiersin.org)
What to watch: Watch for follow-on studies that move these compounds from early mechanistic and feed-additive research into standardized formulations, field trials, safety work, and regulatory pathways for veterinary medicines or claims-backed nutritional products. (frontiersin.org)
Key facts
- Publication
- Frontiers in Veterinary Science
- Publication date
- September 2, 2026
- Article type
- Editorial
- Research topic
- Natural compounds in veterinary therapeutics, volume II
- Focus
- Natural bioactive compounds from plants, animals, microorganisms, and their metabolites
- Main use case
- Potential alternatives or complements to conventional antimicrobials in food-animal systems
- Highlighted studies
- Neurexan, short-chain fructooligosaccharides, essential oils, sodium humate, dandelion polysaccharides, chlorogenic acid, and valonea tannin
- Species mentioned
- Domestic animals, weaned piglets, lambs, broilers, and mice
A new editorial in Frontiers in Veterinary Science puts a spotlight on one of the busiest areas in veterinary pharmacology: natural compounds as potential therapeutics and antibiotic alternatives. Published September 2, 2026, “Natural compounds in veterinary therapeutics, volume II” summarizes a Frontiers research topic curated around bioactive compounds from plants, animals, microorganisms, and their metabolites, with an emphasis on their anti-inflammatory, immunomodulatory, antioxidant, intestinal-health, and growth-related effects. (frontiersin.org)
The backdrop is familiar to anyone in animal health. As production systems have intensified, researchers and industry have faced rising pressure from antimicrobial resistance, mixed infections, consumer expectations, and tighter scrutiny of routine antibiotic use. Frontiers framed the second volume of this topic as a response to that pressure, arguing that natural compounds, including alkaloids, flavonoids, phenolic acids, tannins, terpenes, and polysaccharides, deserve closer study not just as traditional remedies, but as candidates for modern veterinary drug development. (frontiersin.org)
The editorial itself is a synthesis rather than a new experimental study, but it offers a useful map of what researchers are prioritizing. Hao and colleagues highlight chemical profiling work on Neurexan, described as a multicomponent natural veterinary medicinal product used to mitigate stress responses in domestic animals, identifying constituents including caffeine, vitexin, isovitexin, orientin, isoorientin, apigenin, and trigonelline. They also point to production-animal papers showing improved intestinal maturation, mucosal immunity, and microbiota profiles in weaned piglets given short-chain fructooligosaccharides, essential oils, and sodium humate; improved intestinal barrier function and growth performance in lambs receiving dandelion polysaccharides; and improved broiler body weight linked to valonea tannin supplementation and shifts in hepatic transcriptomics and cecal microbiota. (frontiersin.org)
The scope of the topic helps explain why this editorial matters. The associated Frontiers collection was launched after what the publisher described as the success of the first “Natural Compounds in Veterinary Therapeutics” topic, and by early September it had logged more than 10,000 total views. The collection spans both mechanistic and applied work, including a review on natural products for calf diarrhea and an experimental paper on chlorogenic acid’s protective effect in a mouse model of cisplatin-induced acute kidney injury, showing that the field is still broad, exploratory, and not limited to one species or one regulatory endpoint. (frontiersin.org)
Industry-wide, that broad interest matches a longer-running search for antibiotic alternatives in animal agriculture. Prior reviews and expert workshops have found strong momentum behind phytochemicals, probiotics, organic acids, enzymes, and related products, but they’ve also flagged persistent challenges: inconsistent results between farms, incomplete understanding of mechanisms, and the need for better delivery systems and real-world validation. In other words, the enthusiasm is real, but so is the evidence gap between promising bioactivity and dependable clinical or production performance. (link.springer.com)
Why it matters: For veterinarians, nutritionists, and technical teams, this editorial is best read as a research-direction marker, not a clinical endorsement. It reinforces that natural compounds are moving from empiric use toward more chemically characterized, mechanistically framed development. That could eventually expand the toolkit for managing gut health, inflammation, immune function, and antimicrobial-use pressure, particularly in food-animal practice. But the same literature also suggests caution: efficacy can vary by formulation, dose, species, management conditions, and microbiome context, and many candidates still sit closer to feed-additive or investigational status than to validated therapeutic standards. (frontiersin.org)
There’s also a business and regulatory angle. As more of these compounds are studied in defined formulations, the line between supplement-style positioning and medicine-style development may matter more. Chemical characterization, target-oriented pharmacology, safety evaluation, and reproducible field performance are the kinds of evidence that will determine whether promising natural compounds remain niche adjuncts or move toward broader veterinary adoption. That’s especially relevant for practices advising producers and pet parents who may already be asking about “natural” options, often ahead of the evidence. (frontiersin.org)
What to watch: The next step is translation: more controlled field trials, better standardization of active ingredients, safety and dose-ranging work, and clearer regulatory positioning for products that want to make therapeutic or productivity claims in veterinary markets. (frontiersin.org)